Condition: Gastric Cancer · Breast Cancer · Cervical Cancer · Sponsor: Christian Hinrichs
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
This description comes directly from the study's public registry record.
Tobi Adewale · 732-710-2406 · olutobi@cinj.rutgers.edu
Always discuss trial participation with your own doctor first.
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05483491